https://mindmedicinelaw.com/briefing/lilly-s-2-8b-psychedelic-investment-a-new-era-in-trials-20260721-24427The Psychedelic Journalen2026-07-21T15:04:58.867415+00:00Lilly's $2.8B Psychedelic Investment: A New Era in TrialsLilly psychedelic investment, psychedelic clinical trials, neuroplasticity, FDA psychedelic regulation, psychedelic therapy innovation, Schedule I drugs, mental health treatments, pharmaceutical industry, psilocybin research, MDMA trialshttps://mindmedicinelaw.com/briefing/understanding-trd-multi-pillar-approach-in-neuroscience-20260720-24352The Psychedelic Journalen2026-07-21T22:05:41.823937+00:00Understanding TRD: Multi-Pillar Approach in Neurosciencetreatment-resistant depression, multi-pillar framework, antidepressant efficacy, neurological pillars, clinical trials, neuroscience research, TRD treatment strategies, public health implications, psychiatric disorders, mental health treatmenthttps://mindmedicinelaw.com/briefing/new-framework-for-treatment-resistant-depression-multi-pillar-approach-20260720-24354The Psychedelic Journalen2026-07-21T22:05:30.682716+00:00New Framework for Treatment-Resistant Depression: Multi-Pillar Approachtreatment-resistant depression, multi-pillar approach, neural systems, SSRIs, SNRIs, TCA-1, pharmacological strategies, clinical trials, neuroscience, depression treatmenthttps://mindmedicinelaw.com/briefing/substance-trends-in-drivers-victoria-australia-study-20260720-24416The Psychedelic Journalen2026-07-21T15:05:47.159422+00:00Substance Trends in Drivers: Victoria, Australia Studysubstance use trends, MDMA, methylamphetamine, THC, Victoria Australia, road safety, public health policy, driving impairment, toxicology reports, substance-impaired drivinghttps://mindmedicinelaw.com/briefing/ketamine-s-antidepressant-effects-role-of-cx3cl1-cx3cr1-signaling-20260720-24353The Psychedelic Journalen2026-07-21T15:05:31.074881+00:00Ketamine's Antidepressant Effects: Role of CX3CL1/CX3CR1 Signalingketamine, CX3CL1, CX3CR1, antidepressant effects, synaptic plasticity, mood disorders, neuroscience, clinical trials, chemokines, depression treatmenthttps://mindmedicinelaw.com/briefing/hybrid-group-therapy-model-for-psilocybin-in-terminal-care-20260720-24305The Psychedelic Journalen2026-07-21T15:05:20.739083+00:00Hybrid Group Therapy Model for Psilocybin in Terminal Carepsilocybin-assisted therapy, hybrid group therapy, terminally ill patients, public health interventions, community support, psychedelic research, end-of-life care, peer support, group dynamics, clinical trialshttps://mindmedicinelaw.com/briefing/distinct-neural-correlates-of-ketamine-analgesia-and-dissociation-20260720-24412The Psychedelic Journalen2026-07-21T15:05:09.626675+00:00Distinct Neural Correlates of Ketamine Analgesia and Dissociationketamine, analgesia, dissociation, neural correlates, pain management, clinical trials, neuroscience, therapeutic use, side effects, targeted therapieshttps://mindmedicinelaw.com/briefing/psychedelic-drug-market-gains-momentum-with-new-buy-signal-20260719-24254The Psychedelic Journalen2026-07-20T22:03:55.716036+00:00Psychedelic Drug Market Gains Momentum with New Buy Signalpsychedelic drug market, investor confidence, mental health treatment, clinical trials, FDA breakthrough therapy, regulatory oversight, psychedelic research, investment in psychedelics, mental health conditions, ethical considerationshttps://mindmedicinelaw.com/briefing/eeg-complexity-drop-in-dmt-sessions-implications-for-research-20260719-24020The Psychedelic Journalen2026-07-20T22:03:46.450858+00:00EEG Complexity Drop in DMT Sessions: Implications for ResearchEEG complexity, DMT sessions, psychedelic research, Lempel-Ziv complexity, non-stationary data, methodological adjustments, exploratory study, confirmatory replication, psychedelic EEG, research protocolshttps://mindmedicinelaw.com/briefing/eeg-complexity-dip-in-dmt-sessions-implications-for-research-20260719-24019The Psychedelic Journalen2026-07-20T15:05:13.183907+00:00EEG Complexity Dip in DMT Sessions: Implications for ResearchDMT, EEG complexity, psychedelic research, methodological rigor, Lempel-Ziv complexity, procedural factors, neuroscience, clinical trials, data exclusion, replicationhttps://mindmedicinelaw.com/briefing/nigerian-medicinal-plants-drug-discovery-prospects-and-challenges-20260717-23670The Psychedelic Journalen2026-07-21T22:06:13.283952+00:00Nigerian Medicinal Plants: Drug Discovery Prospects and Challengesnigerian medicinal plants, drug discovery, psychotropic activities, ethnopharmacology, bioactive compounds, research collaboration, standardization, clinical trials, international research, pharmacological studieshttps://mindmedicinelaw.com/briefing/psychedelic-research-and-mysticism-implications-and-biases-20260717-23735The Psychedelic Journalen2026-07-21T22:06:06.252532+00:00Psychedelic Research and Mysticism: Implications and Biasespsychedelic research, mysticism, scientific rigor, bias in research, subjective experiences, ethical considerations, research policy, neuroscience, LSD, psilocybinhttps://mindmedicinelaw.com/briefing/integrated-ptsd-and-sud-treatment-for-adolescents-evidence-and-future-20260717-23644The Psychedelic Journalen2026-07-21T22:05:55.128316+00:00Integrated PTSD and SUD Treatment for Adolescents: Evidence and Futureintegrated treatment, PTSD, substance use disorder, adolescents, Risk Reduction Through Family Therapy, RRFT, clinical trials, trauma-focused therapy, COPE-A, mental healthhttps://mindmedicinelaw.com/briefing/visuomotor-mismatch-eeg-responses-implications-for-clinical-trials-20260717-23660The Psychedelic Journalen2026-07-20T22:04:19.203463+00:00Visuomotor Mismatch EEG Responses: Implications for Clinical Trialsvisuomotor mismatch, EEG responses, human cortex, clinical trials, neuroscience, prediction errors, translational research, visual feedback, wireless EEG, virtual realityhttps://mindmedicinelaw.com/briefing/visuomotor-mismatch-eeg-responses-new-insights-in-human-research-20260717-23662The Psychedelic Journalen2026-07-20T22:04:12.466333+00:00Visuomotor Mismatch EEG Responses: New Insights in Human Researchvisuomotor mismatch, EEG, virtual reality, predictive coding, sensory processing, clinical trials, neuroscience, human cortex, animal-human studies, wireless technologyhttps://mindmedicinelaw.com/briefing/combination-therapies-in-parkinson-s-research-new-avenues-20260717-23679The Psychedelic Journalen2026-07-20T22:04:05.411137+00:00Combination Therapies in Parkinson's Research: New Avenuesparkinson's disease, combination therapies, disease-modifying treatments, neurodegenerative research, clinical trials, oncology models, biomarkers in PD, FDA approvals, drug interactions, patient stratificationhttps://mindmedicinelaw.com/briefing/phenomenology-of-ruminations-implications-for-psychiatry-20260716-24359The Psychedelic Journalen2026-07-21T22:06:24.146644+00:00Phenomenology of Ruminations: Implications for Psychiatryruminations, phenomenology, psychiatric research, cognitive processes, psychedelics, therapeutic approaches, lifeworld analysis, mental health, clinical implications, qualitative researchhttps://mindmedicinelaw.com/briefing/5-ht-2a-trkb-signaling-in-psychedelic-effects-implications-20260716-24078The Psychedelic Journalen2026-07-20T15:04:45.280851+00:005-HT(2A)-TrkB Signaling in Psychedelic Effects: Implications5-HT(2A) receptor, TrkB receptor, psychedelic effects, mental health therapies, serotonergic psychedelics, neuroplasticity, clinical trials, therapeutic efficacy, G protein signaling, neurotrophic signalinghttps://mindmedicinelaw.com/briefing/fda-s-new-psychedelic-trial-guidance-impacts-and-implications-20260715-24428The Psychedelic Journalen2026-07-21T15:04:46.056119+00:00FDA's New Psychedelic Trial Guidance: Impacts and ImplicationsFDA guidance, psychedelic trials, clinical trial design, drug development, mental health therapies, regulatory framework, safety monitoring, efficacy assessment, market dynamics, psychedelic researchhttps://mindmedicinelaw.com/briefing/fda-finalizes-psychedelics-guidance-easing-path-to-approval-20260714-24253The Psychedelic Journalen2026-07-20T22:03:36.506012+00:00FDA Finalizes Psychedelics Guidance, Easing Path to ApprovalFDA psychedelics guidance, psychedelic drug approval, clinical trials, regulatory landscape, psychedelic research, therapeutic access, safety and efficacy, policy implications, drug commercialization, psychedelic substanceshttps://mindmedicinelaw.com/briefing/fda-finalizes-psychedelic-trial-guidance-impacts-on-research-20260714-24082The Psychedelic Journalen2026-07-20T15:04:27.435168+00:00FDA Finalizes Psychedelic Trial Guidance: Impacts on ResearchFDA, psychedelic clinical trials, psilocybin, MDMA, mental health, regulatory framework, investment, innovation, safety protocols, ethical considerationshttps://mindmedicinelaw.com/briefing/va-s-new-partnership-on-psychedelic-treatments-for-veterans-20260713-24084The Psychedelic Journalen2026-07-20T15:04:35.769104+00:00VA's New Partnership on Psychedelic Treatments for VeteransVA partnership, psychedelic treatments, veteran mental health, rapid-acting therapies, PTSD treatment, depression treatment, clinical trials, psychedelic research, mental health policy, veteran healthcarehttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-cancer-pain-management-new-insights-20260711-23711The Psychedelic Journalen2026-07-20T15:05:03.804503+00:00Ketamine's Role in Cancer Pain Management: New Insightsketamine, cancer pain, palliative care, systematic review, pain management, clinical guidelines, NMDA receptor, opioid alternative, patient safety, clinical trialshttps://mindmedicinelaw.com/briefing/epigenetic-insights-on-ketamine-mdma-policy-impacts-20260711-23736The Psychedelic Journalen2026-07-20T15:04:53.632574+00:00Epigenetic Insights on Ketamine & MDMA: Policy Impactsketamine, MDMA, epigenetics, psychoplastogens, mental health, clinical trials, therapeutic development, regulatory considerations, neuroscience